Nitrates and other nitric oxide donors in cardiology: current positioning and perspectives

Francesco Iachini Bellisarii1, Francesco Radico, Francesca Muscente

  • 1Institute of Cardiology, "G. d'Annunzio" University - Chieti, Chieti, Italy.

Insights

Nitric oxide donors are vital for cardiovascular disease therapy but face inconsistent use due to tolerance and endothelial dysfunction concerns. Further research is needed to clarify their optimal application and long-term efficacy.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Nitric oxide (NO) donors have a long history in treating cardiovascular diseases.
  • Despite widespread use, cardiologists lack consistent guidelines on their indications and administration.
  • Contradictory pharmacodynamics, including acute efficacy versus long-term tolerance and endothelial dysfunction, create therapeutic challenges.

Purpose of the Study:

  • To review recent biochemical and pathophysiological findings on nitric oxide donors.
  • To re-evaluate the role of nitrates and other NO donors in cardiovascular medicine.
  • To compare international guidelines and identify areas needing further clinical research.

Main Methods:

  • Literature review of biochemical and pathophysiological studies.
  • Analysis of pharmacodynamic properties of NO donors.
  • Comparative review of international clinical guidelines.

Main Results:

  • Acute administration of NO donors is effective.
  • Long-term use may be limited by tolerance and endothelial dysfunction.
  • Inconsistent clinical application highlights a need for clearer guidance.

Conclusions:

  • The long-term efficacy and safety of nitric oxide donors require further investigation.
  • Clarifying indications and optimal administration is crucial for consistent clinical practice.
  • More clinical research is warranted to address current uncertainties regarding NO donor therapy.

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...